Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 2.0.0-ballot built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions
Official URL: https://fevir.net/resources/Library/179632 | Version: 2.0.0-ballot | |||
Active as of 2023-11-26 | Computable Name: | |||
Other Identifiers: FEvIR Object Identifier: 179632, OID:2.16.840.1.113883.4.642.40.44.28.2 | ||||
Usage:Evidence Communication: SystematicReviewExcludedStudies |
||||
Copyright/Legal: https://creativecommons.org/licenses/by-nc-sa/4.0/ |
11 excluded studies
Title: | SystematicReviewExcludedStudies: ADT and Docetaxel vs. ADT alone for metastatic hormone-naive prostate cancer | ||||
---|---|---|---|---|---|
Id: | 179632 | ||||
Version: | 2.0.0-ballot | ||||
Url: | SystematicReviewExcludedStudies: ADT and Docetaxel vs. ADT alone for metastatic hormone-naive prostate cancer | ||||
Accession ID (Computable Publishing LLC) Identifier: |
179632 |
||||
urn:oid:2.16.840.1.113883.4.642.40.44.28.2 |
|||||
Type: |
system: http://terminology.hl7.org/CodeSystem/library-type code: asset-collection display: Asset Collection |
||||
Subject: |
reference: Group/179619 type: http://hl7.org/fhir/StructureDefinition/Group code: SystematicReviewEligibilityCriteria: ADT and Docetaxel vs. ADT alone for metastatic hormone-naive prostate cancer |
||||
Date: | 2023-11-26 18:15:27+0000 | ||||
Publisher: | HL7 International / Clinical Decision Support | ||||
Description: | 11 excluded studies |
||||
Use Context: |
|
||||
Jurisdiction: | 001 | ||||
Copyright: | https://creativecommons.org/licenses/by-nc-sa/4.0/ |
||||
Related Artifacts: |
Derived From |